Name: how antibiotics block bacterial cell walls
Uploaded: 2026-03-12T13:36:02.000Z
Duration: 1 min 23 s
Channel: JoVE

Las paredes celulares bacterianas son generalmente rígidas y están compuestas principalmente de peptidoglicano.Estructuralmente, el peptidoglicano consiste en cadenas largas de glicanos entrecruzadas por péptidos cortos, que forman una malla que protege la célula contra la presión osmótica.Dado que el peptidoglicano es esencial para la supervivencia celular, los antibióticos beta-lactámicos como la penicilina interfieren con su síntesis en células en crecimiento activo.Estos antibióticos contienen un anillo beta-lactámico distintivo de cuatro miembros.Este anillo imita el dipéptido natural D-alanil-D-alanina, un sustrato para la actividad transpeptidasa de proteínas que se unen a la penicilina, o PBPs.Estas proteínas son responsables de la reticulación de cadenas glicanas en la matriz peptidoglicana.Cuando el anillo beta-lactámico se une covalentemente al sitio activo de una PBP, bloquea la reacción de reticulación.Como resultado, la pared celular bacteriana permanece débil e incompleta, lo que hace que las células sean muy vulnerables a la lisis osmótica.Al mismo tiempo, enzimas autolíticas como las hidrolasas de mureína contribuyen aún más a la ruptura de la pared celular defectuosa.

inhibitors of gram-positive cell wall synthesis

Inhibitors of Gram-positive Cell Wall Synthesis

Las paredes celulares bacterianas son estructuras r&#xED;gidas compuestas principalmente de peptidoglicano, un pol&#xED;mero reticular que proporciona resistencia mec&#xE1;nica y mantiene la forma celular. La s&#xED;ntesis de peptidoglicano es un proceso crucial para el crecimiento bacteriano y constituye un objetivo principal de muchos antibi&#xF3;ticos.
Mecanismo de acci&#xF3;n de los antibi&#xF3;ticos betalact&#xE1;micos
Los antibi&#xF3;ticos betalact&#xE1;micos, como la penicilina, inhiben la s&#xED;ntesis de peptidoglicano en c&#xE9;lulas en crecimiento activo. Estos antibi&#xF3;ticos comparten un anillo betalact&#xE1;mico caracter&#xED;stico de cuatro miembros que imita estructuralmente el dip&#xE9;ptido D-alanil-D-alanina, el sustrato natural de la enzima transpeptidasa, tambi&#xE9;n conocida como prote&#xED;na fijadora de penicilina, o PBP. Al unirse irreversiblemente al sitio activo de esta enzima, los betalact&#xE1;micos impiden la reticulaci&#xF3;n de las cadenas pept&#xED;dicas dentro del peptidoglicano. Esta interrupci&#xF3;n detiene el ensamblaje de la pared celular y activa las hidrolasas de mure&#xED;na, enzimas que degradan el peptidoglicano, lo que finalmente conduce a la lisis de la c&#xE9;lula bacteriana.
Los betalact&#xE1;micos se clasifican en cuatro grupos principales: penicilinas, cefalosporinas, monobact&#xE1;micos y carbapen&#xE9;micos. Las penicilinas (p. ej., penicilina G, ampicilina) fueron los primeros betalact&#xE1;micos desarrollados y se utilizan principalmente para tratar infecciones por bacterias grampositivas, aunque muchas han ampliado su cobertura frente a bacterias gramnegativas. Las cefalosporinas (p. ej., cefazolina, ceftriaxona) ofrecen una actividad de espectro m&#xE1;s amplio y una mayor resistencia a las enzimas betalactamasa producidas por las bacterias. Los monobact&#xE1;micos (p. ej., aztreonam) son activos principalmente frente a bacterias gramnegativas y son especialmente &#xFA;tiles en pacientes con alergia a la penicilina. Los carbapen&#xE9;micos (p. ej., meropenem, imipenem) poseen el espectro m&#xE1;s amplio de todos los betalact&#xE1;micos y suelen reservarse para infecciones graves o multirresistentes.
Debido a su diversidad estructural y amplia utilidad cl&#xED;nica, los betalact&#xE1;micos siguen estando entre las clases de antibi&#xF3;ticos m&#xE1;s utilizadas y estudiadas en la medicina moderna.
Mecanismo de acci&#xF3;n de los antibi&#xF3;ticos glucop&#xE9;ptidos
Los antibi&#xF3;ticos glucop&#xE9;ptidos, como la vancomicina, la teicoplanina y la dalbavancina, act&#xFA;an mediante un mecanismo distinto del de los betalact&#xE1;micos. Estos agentes se unen directamente a los extremos D-alanil-D-alanina de los precursores del peptidoglicano, formando complejos estables que impiden el acceso enzim&#xE1;tico al sustrato. Esta uni&#xF3;n bloquea est&#xE9;ricamente la actividad de la transglicosilasa, la enzima responsable de catalizar la elongaci&#xF3;n de las cadenas gluc&#xE1;nicas, y de la transpeptidasa, que media la reticulaci&#xF3;n pept&#xED;dica. Como resultado, se detienen tanto la polimerizaci&#xF3;n como la reticulaci&#xF3;n en la bios&#xED;ntesis de la pared celular.
A diferencia de los betalact&#xE1;micos, los glucop&#xE9;ptidos no inhiben directamente estas enzimas; en cambio, act&#xFA;an protegiendo el sitio diana. Este mecanismo indirecto resulta particularmente ventajoso frente a bacterias que han adquirido resistencia a los betalact&#xE1;micos mediante la producci&#xF3;n de betalactamasas o la alteraci&#xF3;n de las prote&#xED;nas fijadoras de penicilina, o PBP. Los glucop&#xE9;ptidos son m&#xE1;s eficaces frente a microorganismos grampositivos, ya que su gran tama&#xF1;o molecular y su hidrofilicidad les impiden penetrar en la membrana externa de las bacterias gramnegativas.

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains ...

https://cloudfront.jove.com/files/ftp_upload/40859/40859_article_thumb_40859.jpg

inhibitors-of-gram-positive-cell-wall-synthesis

Education

Educación

JoVE Core

Microbiology

Microbiología

Unit

Unidad

Antimicrobial Agents

Agentes antimicrobianos

KEY TERMS AND CONCEPTS

TÉRMINOS Y CONCEPTOS CLAVE

how antibiotics block bacterial cell walls

Bacterial cell walls are rigid structures built mainly from peptidoglycan. This mesh-like polymer gives bacteria strength and helps maintain cell shape. Because peptidoglycan synthesis is essential for growth, it is a major target for antibiotics.

Beta-lactam antibiotics, such as penicillin, stop peptidoglycan synthesis in actively growing cells. They have a four-membered beta-lactam ring that mimics the D-alanyl-D-alanine dipeptide, which is the natural substrate for transpeptidase, also called a penicillin-binding protein (PBP). By binding irreversibly to the enzyme’s active site, these drugs block cross-linking between peptide chains. That disruption halts cell wall assembly, activates murein hydrolases that break down peptidoglycan, and can lead to bacterial cell lysis.

Beta-lactams are grouped into four main classes: penicillins, cephalosporins, monobactams, and carbapenems. Penicillins, such as penicillin G and ampicillin, were the first beta-lactams developed and are mainly used for Gram-positive infections, although many now also cover Gram-negative bacteria. Cephalosporins, such as cefazolin and ceftriaxone, have broader activity and are more resistant to beta-lactamase enzymes made by bacteria.

Monobactams, such as aztreonam, act mainly against Gram-negative bacteria and are especially useful in patients with penicillin allergies. Carbapenems, such as meropenem and imipenem, have the broadest spectrum of the beta-lactams and are usually reserved for severe or multidrug-resistant infections. Because of their structural variety and clinical value, beta-lactams remain one of the most studied antibiotic groups in modern medicine.

Glycopeptide antibiotics work in a different way. Drugs such as vancomycin, teicoplanin, and dalbavancin bind directly to the D-alanyl-D-alanine ends of peptidoglycan precursors. This creates a stable complex that blocks enzyme access to the substrate and prevents both transglycosylase, which lengthens glycan strands, and transpeptidase, which makes peptide cross-links.

Unlike beta-lactams, glycopeptides do not block these enzymes directly. Instead, they shield the target site and stop both polymerization and cross-linking during cell wall biosynthesis. This indirect action can be useful against bacteria that resist beta-lactams by producing beta-lactamases or changing their PBPs. Glycopeptides work best against Gram-positive organisms because their large size and hydrophilic nature keep them from crossing the outer membrane of Gram-negative bacteria.

How Antibiotics Block Bacterial Cell Walls

how-antibiotics-block-bacterial-cell-walls

Bacterial cell walls are rigid structures built mainly from peptidoglycan. This mesh-like polymer gives bacteria strength and helps maintain cell shape. Because peptidoglycan synthesis is essential for growth, it is a major target for antibiotics. Beta-lactam antibiotics, such as penicillin, stop peptidoglycan synthesis in actively growing cells. They have a four-membered beta-lactam ring that mimics the D-alanyl-D-alanine dipeptide, which is the natural substrate for transpeptidase, also...

inhibitors of bacterial protein synthesis

inhibitors-of-bacterial-protein-synthesis

Aminoglycosides: How They Stop Bacteria

Aminoglycosides are bactericidal antibiotics that stop bacteria by targeting the ribosome and disrupting protein synthesis. They are highly potent drugs made of amino-modified sugars linked by glycosidic bonds to an aminocyclitol core, such as 2-deoxystreptamine or streptamine. Their strong positive charge helps them bind tightly to the negatively charged phosphate backbone of ribosomal RNA, especially the 16S rRNA of the 30S subunit in the bacterial 70S ribosome. These antibiotics act at the...

inhibitors of bacterial dna synthesis

Fluoroquinolone Antibiotics and Bacterial DNA

Fluoroquinolone antibiotics target bacterial DNA replication by blocking two key type II topoisomerases: DNA gyrase and topoisomerase IV. These enzymes help bacteria manage DNA supercoiling and separate chromosomes during replication. When they are disrupted, bacterial pathogens cannot copy DNA efficiently and infection can spread less effectively. Fluoroquinolones are synthetic versions of quinolones. They work by stabilizing the short-lived DNA-enzyme cleavage complex, which stops strand...

inhibitors of viral protein synthesis

Interferons Block Viral Replication

Interferons block viral replication by shutting down protein synthesis and activating the cell’s antiviral defenses. Viruses need the host cell’s translational machinery to make proteins, because they do not have the machinery to do this on their own. When a virus is detected, infected cells release interferons, which are cytokines, or signaling proteins, that warn nearby uninfected cells. Interferons bind to receptors on nearby cells and activate the JAK-STAT signaling pathway. This turns on...

inhibitors of virion release

Neuraminidase Inhibitors and Flu Spread

Influenza viruses spread when new virions leave an infected cell and reach nearby cells. Influenza A and B are negative-sense, single-stranded RNA viruses with segmented genomes. They depend on two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), to infect cells, make new viral particles, and release them. HA starts infection by binding to sialic acid on the surface of host epithelial cells. This binding helps the virus enter the cell by receptor-mediated endocytosis. After...

antiviral nucleoside inhibitors

How Antiviral Drugs Stop Viral Replication

Antiviral nucleoside inhibitors stop viruses by blocking DNA or RNA synthesis. These drugs are structural analogs, which means they look like natural nucleosides, the building blocks cells use to make genetic material. Because they resemble host nucleosides, they can interfere with viral polymerases and disrupt viral genome replication. Acyclovir is a guanosine analog with a three-carbon acyclic side chain. It mainly targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2...

antifungal agents

Amphotericin B and Fungal Membranes

Amphotericin B targets fungal cell membranes by binding to ergosterol, a sterol found mainly in fungal plasma membranes. Its amphipathic structure helps this selective binding. It has a hydrophobic polyene-lactone ring and a hydrophilic region with mycosamine and carboxylic acid groups. Weak binding to cholesterol can also affect human cells and helps explain the drug’s toxicity. One way amphotericin B kills fungi is through pore formation. In this model, amphotericin B-ergosterol complexes...

mechanism of antibiotic resistance in mrsa

mechanism-of-antibiotic-resistance-in-mrsa

How Bacteria Outsmart Antibiotics

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working. Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower...

anthelminthic agents

Helminth Drugs and How They Work

Helminth drugs work by attacking the weak points of parasitic worms. These anthelmintic medicines are different from drugs used against protozoa, because they are usually aimed at mature helminths rather than fast-dividing cells. They target the worm’s movement, glucose use, and microtubule structure to stop survival, reproduction, and location inside the host. Benzimidazoles are broad-spectrum anthelmintics that block tubulin polymerization, which means they interfere with microtubules, the...

clinical significance of antibiotic resistance

clinical-significance-of-antibiotic-resistance

MRSA: Host Adaptation and Transmission

MRSA, or methicillin-resistant Staphylococcus aureus, is a major public health threat. It resists beta-lactam antibiotics because it carries the mecA gene inside the staphylococcal cassette chromosome mec, or SCCmec. The mecA gene makes penicillin-binding protein 2a, which reduces how well methicillin and related beta-lactam drugs can bind. MRSA has spread into separate clonal lineages that affect both humans and animals. These lineages fit the One Health idea, which links human, animal, and...

inhibitors of virion maturation and assembly

inhibitors-of-virion-maturation-and-assembly

HIV Protease Inhibitors and Maturation

HIV protease inhibitors block a key step in virus maturation. In human immunodeficiency virus (HIV), infected cells make two long precursor proteins called polyproteins. These are Gag and Gag-Pol. Gag provides the virus structure. Gag-Pol carries important viral enzymes, including reverse transcriptase, integrase, and protease. After these polyproteins are made, they move to the host cell membrane. There, they help build an immature viral particle that buds from the cell surface. Budding...

antiprotozoal agents

Leishmaniasis and Trypanothione Reductase

Leishmaniasis is a parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. Treatment often relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. The way these drugs work has not been fully clear. One important target is trypanothione reductase, or TR, an enzyme that helps keep Leishmania in redox balance. TR is not found in mammalian hosts, so it is a...

key terms and concepts

Learn how beta-lactams and glycopeptides disrupt bacterial cell wall synthesis, from penicillin binding proteins to vancomycin’s action on peptidoglycan.

How Antibiotics Block Bacterial Cell Walls | JoVE K12

JoVE Core Microbiology provides an engaging introduction to the microbial world and its influence on health, industry, and the environment. This comprehensive collection covers key concepts such as microbial structure, metabolism, genetics, and ecology. It introduces essential laboratory techniques and microscopy methods through visually engaging animations. Corresponding scientist-in-action videos bridge classroom concepts with real-world research and applications.

microbiology

How Antibiotics Block Bacterial Cell Walls

Description

Transcript

Tags